What is the environmental impact of HFA 152a? Have inhalation safety studies been completed? Can HFA 152a be handled safely? Is HFA 152a compatible with existing pMDI valves? Is HFA 152a currently available? Is a DMF available for HFA 152a? Will 152a cost more than 134a and 227?
A pharmaceutical composition is described. The composition comprises: (i) a drug component comprising at least one pharmaceutically acceptable salt of giycopyrrolate; and (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a).CORR, STUART...
The composition comprises: (i) a drug component comprising at least one salmeterol compound selected from salmeterol and the pharmaceutically acceptable derivatives thereof; and (ii) a propellant component comprising 1,1 -difluoroethane (HFA-152a).CORR, STUART...
The composition comprises: (i) a drug component comprising at least one indacaterol compound selected from indacaterol and the pharmaceutically acceptable derivatives thereof; and (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a).CORR, STUART...